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Abstract
Background: Sets of genes that are known to be associated with each other can be used to interpret microarray
data. This gene set approach to microarray data analysis can illustrate patterns of gene expression which may be
more informative than analyzing the expression of individual genes. Various statistical approaches exist for the
analysis of gene sets. There are three main classes of these methods: over-representation analysis, functional class
scoring, and pathway topology based methods.
Methods: We propose weighted hypergeometric and weighted chi-squared methods in order to assign a rank to
the degree to which each gene participates in the enrichment. Each gene is assigned a weight determined by the
absolute value of its log fold change, which is then raised to a certain power. The power value can be adjusted as
needed. Datasets from the Gene Expression Omnibus are used to test the method. The significantly enriched
pathways are validated through searching the literature in order to determine their relevance to the dataset.
Results: Although these methods detect fewer significantly enriched pathways, they can potentially produce more
relevant results. Furthermore, we compare the results of different enrichment methods on a set of microarray
studies all containing data from various rodent neuropathic pain models.
Discussion: Our method is able to produce more consistent results than other methods when evaluated on
similar datasets. It can also potentially detect relevant pathways that are not identified by the standard methods.
However, the lack of biological ground truth makes validating the method difficult.
Introduction
Due to their ability to provide comprehensive snapshots of
cellular activity, microarrays have become a widely utilized
tool in bio-medical sciences. Microarray-based gene
expression detection has been used for biomarker discov-
ery as well as diagnostic and prognostic purposes [1-4].
Online microarray experiment repositories such as Gene
Expression Omnibus (GEO) [5,6], ArrayExpress [7], and
Stanford Microarray Database (SMD) [8] are invaluable
resources containing gene expression profiles that span
multiple developmental stages, experimental conditions,
and model organisms [9,10]. There are numerous chal-
lenges presented by the expanding availability of microar-
ray data. The difficulty of interpreting the lists of
significant genes produced by microarray experiments is a
major challenge. The staggering number and diversity of
the differentially expressed genes can be hard to interpret
in a biologically meaningful way. As a result several statis-
tical methods for gene set enrichment have been devel-
oped. The set of differentially expressed genes is compared
to gene sets from various databases including Gene Ontol-
ogy (GO) [11] or the Kyoto Encyclopedia of Genes and
Genomes (KEGG) [12].
Huang et al. reviewed and classified 68 available tools for
the statistical analysis of gene sets [13]. Huang classified
the available pathway enrichment methods into three cate-
gories: over-representation analysis (ORA), functional class
scoring (FCS), and pathway topology (PT) based methods
[13,14]. In ORA, a list of genes is compiled by selecting
genes based on their significance, fold change, or both.
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ORA techniques seek to identify whether the gene list is
over-represented in a gene set or pathway. In ORA
approaches, if k genes from the list are found in a pathway
then the probability of finding k or more genes is calcu-
lated. The resulting p-values are used to determine whether
or not a pathway or gene set is significantly enriched. The
probability can be calculated using the chi-squared distribu-
tion, Fisher’s Exact Test, the binomial probability distribu-
tion, or the hypergeometric distribution [13].
In functional class scoring approaches, such as Gene Set
Enrichment Analysis (GSEA) [15], all genes are considered
when calculating enrichment instead of a pre-selected list
[14,15]. This can deliver improved statistical power [13].
In the FCS approaches, genes are assigned ranks. In
GSEA, a gene’s rank is determined by its correlation with
the experimental sample classifications. When calculating
the significance of a gene set, the null hypothesis is that
the genes in a set are randomly distributed throughout the
ranked list of genes from the microarray experiment.
GSEA creates a null distribution by randomly permuting
the labels of the samples and producing lists of genes
ranked by their correlation with the newly shuffled sample
labels. Using this null distribution to estimate the signifi-
cance is analogous to a weighted Kolmogorov-Smirnov-
like statistic [15]. In contrast, Parametric Analysis of Gene
Set Enrichment (PAGE) determines a z-score for a set and
uses normal distribution to determine significance [16].
Both ORA and FCS approaches ignore the connections
between genes in a pathway, however PT-based approaches
integrate the information contain in the edges of a pathway
when determining the enrichment. The disadvantage of
PT-based approaches is that they cannot be applied to the
Gene Ontology [14]. ScorePAGE computes a score that
represents the similarity between pairs of genes, and then
divides this score by the number of edges between the two
genes [14,17]. Another approach is that of Signaling Path-
way Impact Analysis (SPIA), which computes a “perturba-
tion factor” for each gene in a pathway. This is given by
the change in expression of the gene and by a linear func-
tion of the perturbation factors of all the other genes in the
pathway. The “impact factor” of the pathway is a statistic
calculated by taking the sum of the perturbation factors of
the genes in the pathway [14,18].
We have previously proposed a method for enriching
gene sets that is a hybrid of over-representation and
functional class scoring [19]. Our method requires the
contribution of all the genes in the dataset. Each gene
contributes to the enrichment score in proportion to its
fold change. Like ORA we calculate significance using
the hypergeometric or chi-square distribution; however
our method weighs the probability calculation by the fold
change of the genes. In our method each gene is assigned
a score based on its fold change, and we create a pseudo
pathway, which is proportionally larger than the original
pathway. We then calculate the significance of sampling
the sum of the scores of the genes from the larger pseudo
pathway.
We applied this pathway enrichment methodology in
order to perform a meta-analysis of rodent neuropathic
pain microarray experiments. Neuropathic pain is a
chronic condition resulting from damage to any part of
the nervous system or from diseases affecting an area of
the nervous system. Neuropathic pain is typically accom-
panied by inflammation [20] and sensory and motor
dysfunction [21]. Up to eight percent of the general popu-
lation is affected by neuropathic pain [22,23]. While there
is no clear etiology for neuropathic pain, spinal cord
injury, diabetes, alcoholism, chemotherapy, chronic viral
infection, transverse myelitis, and strokes are common
causes. Due to the complex etiology and symptoms of
neuropathic pain and its poorly understood mechanisms,
the classification of chronic pain syndromes has remained
largely subjective. Common treatments are able to pro-
duce better than moderate pain relief in only one third of
patients [24]. Treatments such as opiates, tricyclic antide-
pressants, anti-convulsants, anti-epileptics, topical analge-
sics, and NMDA-antagonists are used despite their limited
efficacy and harmful side-effects [25,26]. There are several
rodent models of neuropathic pain such as nerve ligation,
chronic constriction, and spared nerve injury [27,28].
Methods
Gene ID mapping
Before we could begin performing enrichment analysis, we
needed to construct a back-end database containing rele-
vant information from various databases. Towards this
end, we stored all the KEGG pathways and the genes
involved in each pathway in a database. We further cre-
ated a database to map the correspondence of Entrez
genes with Affymetrix probe identifiers to enable gene
identifier conversion. The correspondence between Entrez
gene identifiers and KEGG gene identifiers was also
mapped. Ultimately, a database for the KEGG pathway
information and a database for gene identifier conversion
were created in SQLite. Only genes from Homo Sapiens,
Rattus Norvegicus, and Mus Musculus were included in
the database. We mapped Affymetrix gene identifiers to
Entrez Gene identifiers for Affymetrix microarray datasets
with binary classifications obtained from the Gene Expres-
sion Omnibus (GEO) [6]. Because multiple Affymetrix
probes can map to a single Entrez Gene, we took the
mean of the fold-change of the corresponding probes and
the minimum of their p-values.
Enrichment
Before calculating enrichment, we quantile-normalized
the raw data and computed the fold change of each
gene. A two-tailed Student’s t-test with an alpha value
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of 0.01 was used to identify significant differentially
expressed genes. The standard hypergeometric test was
used to perform enrichment for comparison to our
method. The probability of finding X >k significant
genes in a particular gene set or pathway is calculated
as follows:
















where N is the number of genes on the array, m is the
number of significant genes, n is the number of genes in
the particular KEGG pathway, and k is the number of
genes that are both significant and present in the parti-
cular KEGG pathway. Thus we were able to calculate
the significance of the enrichment of the KEGG path-
ways and rank them by their significance.
For our weighted hypergeometric and chi-squared
tests, each gene was assigned a score calculated as
shown in the formula below:
gi =
∣∣log2 (fold change (genei))∣∣a (2)
The power, a, is an adjustable parameter. In each
dataset, a value Q was calculated by taking the maxi-
mum of the gene scores in the pathway. The hypergeo-
metric distribution is a discrete probability distribution
function; however our gene scores existed on a continu-
ous scale. Thus, we had to ensure that our gene scores
were discrete. Rounding the values of the gene scores to
the nearest whole number accomplished this. For each
KEGG pathway, we calculated k by taking the sum of
the scores of the genes involved in the pathway, as





where n is the number of genes in a particular KEGG
pathway. Each individual gene’s score gi, corresponded
to the number of copies of that gene that were consid-
ered significant in the pseudo pathway. The value k cor-
responds to the total number of significant genes in the
pseudo pathway. We then utilized the hypergeometric
distribution to calculate the probability that the pathway
score was greater than k, according to the formula
below
















where all variables represent the same quantities that
they do in equation 1, and all quantities are rounded to
the nearest whole number. We ranked the pathways
using this p-value.
A similar approach was applied to the chi-squared statis-
tic. The chi-squared distribution represents an approxima-
tion of the exact probability of sampling without
replacement, which is determined by the hypergeometric
distribution. The chi-squared statistic was sometimes used
because of the difficulty of computing hypergeometric
probabilities for large populations. The chi-squared sta-
tistic [29] is determined using the 2x2 table shown in






We utilize a chi-squared distribution with 1 degree of
freedom, which is calculated from Table 1 as follows:
df = (r − 1) (c − 1) (6)
where r is the number of rows in the table and c is the
number of columns. We compute a weighted chi-squared
statistic by constructing a table similar to Table 1, but in
the place of the significant genes column we use the path-
way score calculated by Equation 5 and the sum of the
scores of all the genes on the array. Unlike the hypergeo-
metric probability distribution, the chi-squared probability
distribution is continuous. We did not need to discretize
our data.
Experiments and results
We tested these weighted enrichment approaches using a
microarray dataset from that that compares C. Pneumo-
niae infected dendritic cells and mock-infected controls
[30]. The authors of the original dataset did not conduct
enrichment analysis during their study. The enriched path-
ways resulting from standard hypergeometric enrichment
were compared to the enriched pathways resulting from
weighted hypergeometric and chi-squared enrichment.
The top-10 most significant pathways detected by hyper-
geometric enrichment are shown in Table 2. Table 3






In Pathway n11 n12 N1r = n11 + n12
Not in
Pathway
n21 n22 N2r = n21 + n22
N1c = n11+n21 N2c = n12+n22 N = n11+n12+n21
+n22
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shows the top-10 pathways enriched by the weighted
hypergeometric method. Table 4 shows the top-10 path-
ways produced by weighted chi-squared enrichment.
Hypergeometric enrichment detected 56 significant
pathways (p < 0.05). Table 3 shows that weighted hyper-
geometric enrichment only detected four significant
pathway (p < 0.05).Weighted chi-squared enrichment
only detected one significant pathway, as shown in
Table 4. This significant pathway, which contained only
2 significant genes, was ranked 132 by hypergeometric
enrichment and had a p-value of 0.23. The two most
significant pathways according to weighted hypergeo-
metric enrichment were both glycosphingolipid bio-
synthesis pathways, which were not detected by the
standard method because none of the genes in the path-
way were significant despite high fold-change. Despite
having no significant genes (p < 0.01), the mean expres-
sion change of the genes in the glycosphingolipid bio-
synthesis–globo series pathway was over 3-fold; specific
values for significance and fold-change for the genes in
this pathway are shown in Table 5. The glycosphingoli-
pid biosynthesis–globo series pathway [12] is shown in
Figure 1. Additionally, there exist both highly upregu-
lated and downregulated genes in the pathway.
We performed a literature search to assess the rele-
vance of the top-10 pathways produced by the various
methods. Since the dataset utilized involved the infection
of cells, pathways related to the immune system should
be enriched. Hypergeometric enrichment identified two
potentially relevant pathways: natural killer cell mediated
cytotoxicity and V. Cholerae infection. The top-2 path-
ways produced by this method were nitrogen metabolism
and biotin metabolism. Weighted hypergeometric enrich-
ment identified both types of glycosphingolipid biosynth-
esis as the top-2 pathways, with a glycosaminoglycan
degradation related pathway as the third ranked pathway.
Glycans and glycosylation are essential components of
Table 2 The results of hypergeometric enrichment of the
genes that are significant at the 0
Pathway p-value FDR # of significant
genes
Nitrogen metabolism 0.000329 0.080509 4
Biotin metabolism 0.000815 0.099656 1
Prion diseases 0.002291 0.186713 4
Natural killer cell mediated
cytotoxicity
0.002489 0.152139 9




ErbB signaling pathway 0.002747 0.095982 7
Osteoclast differentiation 0.002976 0.090963 9
Non-small cell lung cancer 0.003207 0.087127 5
Vibrio cholerae infection 0.00428 0.104663 5
Table 3 The results of weighted hypergeometric
enrichment of the C.Pneumonia infection dataset
Pathway P-Value FDR Pathway
Score
Glycosphingolipid biosynthesis - globo
series
0.011041 1 22
Glycosphingolipid biosynthesis - ganglio
series
0.01264 1 23
Glycosaminoglycan degradation 0.019259 1 26
Pantothenate and CoA biosynthesis 0.030492 1 24
D-Arginine and D-ornithine metabolism 0.056692 1 2
Protein export 0.063533 1 26
Vitamin digestion and absorption 0.075501 1 29
Thiamine metabolism 0.101094 1 6
Primary bile acid biosynthesis 0.108834 1 19
Ether lipid metabolism 0.114348 1 40
Table 4 The results of weighted chi-squared enrichment
of the C. Pneumonia infection dataset
Pathway P-Value FDR Pathway
Score
Drug metabolism - cytochrome P450 0.034493 1 35.97864
Amyotrophic lateral sclerosis (ALS) 0.076237 1 34.94194
Pathways in cancer 0.081381 1 268.3321
Cell adhesion molecules (CAMs) 0.102061 1 97.04176
Calcium signaling pathway 0.114357 1 140.0101
NOD-like receptor signaling pathway 0.131509 1 39.68646






Glycosphingolipid biosynthesis - globo
series
0.145623 1 22.14654
Axon guidance 0.173427 1 102.641
Table 5 The p-values and fold changes of the genes in
the glycosphingolipid biosynthesis-globo pathway
Entrez Gene ID Symbol P-Value Fold Change
2523 Fut1 0.154618 1.079052
2524 FUT2 0.085096 1.506772
2717 Gla 0.048796 7.793774
3073 HexA 0.271048 5.073008
3074 Hexb 0.166863 7.790576
4668 nagA 0.063709 2.171953
6482 ST3GAL1 0.275852 2.535963
6483 ST3GAL2 0.13051 2.067693
6489 ST8SIA1 0.357908 7.755918
8706 B3galnt1 0.029243 0.863497
10317 B3galt5 0.475799 3.853211
10690 fut9 0.275609 1.418501
26301 Gbgt1 0.338454 0.097302
53947 A4GALT 0.621914 0.619847
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the antigen-presenting function of dendritic cells [31].
Glycosphingolipids are proteins present in the plasma
membrane that are known to be involved in immune
function. They can act as cell-surface antigens [32,33].
The standard method failed to detect these pathways;
where as the weighted hypergeometric method uncov-
ered the action of these pathways and helped elucidate
mechanisms of the infection of the cells. In addition,
Figure 1 The glycosphingolipid biosynthesis-globo series KEGG pathway, with Entrez Genes detected on the array colored pink; this was the
top-ranked pathway by weighted hypergeometric enrichment.
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despite finding fewer significant pathways the weighted
chi-squared method also detected the glycosphingolipid
synthesis pathways among its top-10 pathways, although
at lower ranks than weighted hypergeometric enrich-
ment. These pathways, which are the top-ranked path-
ways by the weighted hypergeometric method, are more
biologically relevant than the top-ranked pathways gener-
ated by the standard hypergeometric method.
We further identified 4 datasets from the Gene Expres-
sion Omnibus pertaining to rodent models of neuropathic
pain. The datasets included studies utilizing spinal nerve
ligation, sciatic nerve ligation, chronic constriction injury,
and spared nerve injury neuropathic pain models
[25,26,34,35]. Although only 4 studies were utilized, some
studies contained multiple neuropathic pain models, so we
examined differential gene expression across 5 different
conditions. Hypergeometric, chi-squared, weighted hyper-
geometric, and weighted chi-squared enrichment were
applied to each of the dataset. The top-10 most signifi-
cantly enriched pathways were considered. The common
pathways identified by each method in each of the datasets
were tabulated. A power of 1 was used for the weighted
enrichments, and a p-value cut-off of 0.01 was used for
the unweighted enrichment. Figure 2 shows all of the
KEGG pathways that were detected by hypergeometric
enrichment in at least 2 datasets. Only, the ribosome, Par-
kinson’s disease, oxidative phosphorylation, and TCA
cycle pathways were identified in 2 different datasets.
Figure 3 shows the KEGG pathways identified in at least 2
or more datasets by the chi-squared test. Only the Parkin-
son’s disease and oxidative phosphorylation pathways were
identified by both chi-squared and hypergeometric enrich-
ment. Figure 4 shows the results of applying weighted
hypergeometric enrichment with a power of 1. Weighted
hypergeometric enrichment is able to detect pathways
most consistently. The lysine biosynthesis pathway is sig-
nificantly enriched in all datasets. Unlike the other enrich-
ment methods, weighted hypergeometric enrichment
identified completely different pathways consisting mainly
of metabolic pathways, and pathways relating to amino
acids. Figure 5 contains the results of weighted chi-
squared enrichment. Parkinson’s disease and oxidative
phosphorylation are both consistently enriched by the
weighted chi-squared method.
Weighted hypergeometric enrichment detected the
butirosin and neomycin biosynthesis pathway in 3 data-
sets, which is shown in Figure 6. This pathway was not
enriched by any of the other methods in 2 or more data-
sets. There is evidence for action by neomycin on the ner-
vous system; it can block the capsaicin response of rat
dorsal root ganglion neurons and can block N-type and
P-type voltage dependent calcium channels [36]. Neomycin
may also be a transient receptor ion channel 1 (TRPV1)
antagonist. TRPV1 is a ligand-gated cation channel
involved in multiple pain sensation mechanisms, as a
result neomcycin can alleviate pain responses [37]. Fatty
Figure 2 A compilation of the pathways selected by hypergeometric enrichment from the rodent neuropathic pain model datasets. Only
pathways enriched in 2 or more datasets are shown.
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acid biosynthesis is enriched in two datasets, and fatty acid
metabolites can induce pain by stimulating the transient
receptor potential A1 channel (TRPA1) [38]. The fact that
these two pathways, which have been previously associated
with neuropathic pain, are only identified by weighted
hypergeometric enrichment demonstrates the potential
advantage of weighted hypergeometric enrichment in
identifying relevant pathways missed by the standard
methods.
Discussion
Weighted hypergeometric and chi-squared enrichment
extend over-representation analysis to include change in
expression of the genes and include all genes instead of a
pre-selected list. These approaches enable every gene to
contribute to the enrichment in proportion to their fold-
change. Changing the power parameter enables one to
adjust how much the expression change of the genes
contributes to the enrichment score of the pathway. Our
approach combines ORA and FCS methodologies. Unlike
GSEA [15] our methods can detect pathways comprised of
both up and down regulated genes by means of the score
calculated for each gene. This is because we consider only
the magnitude of expression change and not its direction
with our score. There already exists a modification of
GSEA that allows enrichment of pathways with bidirec-
tional gene expression [39].
Weighted enrichment methods are much more conser-
vative than unweighted methods. Because the weighted
hypergeometric enrichment methods are so conservative,
they produce no significant results when corrected for
multiple comparisons. The Benjamini-Hochberg false dis-
covery correction [40] was applied to the weighted enrich-
ment, and the results are depicted in Tables 2, 3, 4. Table
2 shows that after false discovery rate (FDR) correction
there are no significant pathways (p < 0.05), and that each
Figure 3 A compilation of the pathways selected by chi-squared enrichment from the rodent neuropathic pain model datasets. Only pathways
enriched in 2 or more datasets are shown.
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pathway has an FDR-corrected p-value of 1. However, the
FDR correction is not suitable for application to enrich-
ment analysis because FDR has a high variability and
should be applied to a larger number of p-values than
those generated by enrichment [41]. Furthermore, it has
been shown that most multiple comparison corrections
decrease the power of the analysis and are also too conser-
vative [13,42]. Additionally, the p-values resulting from
enrichment analyses can be fragile and sensitive to non-
statistical aspects of their calculation such as the data
sources or the mapping of gene names between different
conventions; these issues cannot be resolved by correction
for multiple comparisons [13]. Huang et al. advise using
prior biological knowledge to assess the enriched path-
ways, and that the results of enrichment should only be
guidelines for an investigator [13]. Thus, FDR values were
only included to be thorough when describing the results
of these methods. We advise considering only the top-10
pathways instead of multiple comparison correction.
Furthermore, we evaluated the consistency of our methods
by considering the top-10 pathways enriched in data from
several similar experiments. We were able to demonstrate
that weighted hypergeometric enrichment produced the
most consistent results.
Validating the weighted enrichment methods has
proved to be challenging because there is no ground
truth to compare the enriched pathways against. As a
result, validation of the methods was performed based
on literature search, which is not a complete or objec-
tive analysis. Literature search-based validation is biased
towards already known pathways. There is no way of
knowing whether pathways enriched by the dataset that
have not been previously identified in the literature are
actually associated with the disease or are falsely identi-
fied as enriched. Furthermore, our method is still sensi-
tive to the handling of gene identifier mapping. Another
Figure 4 A compilation of the pathways selected by weighted hypergeometric enrichment from the rodent neuropathic pain model datasets.
Only pathways enriched in 2 or more datasets are shown.
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Figure 5 A compilation of the pathways selected by weighted chi-squared enrichment from the rodent neuropathic pain model datasets. Only
pathways enriched in 2 or more datasets are shown.
Figure 6 The butirosin and neomycin biosynthesis pathway. The nodes identified in the datasets are colored in pink. The node 2.7.11
corresponds to 3 different rat genes that were identified as significant.
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drawback of this methodology is that it ignores the
topology of the pathways. It is possible, for example,
that an increase in the expression of a gene could be
canceled out by a decrease in the expression of a down-
stream gene that is up regulated by the first gene. There
is no way to address this situation when using our
method. However, this drawback does not apply to the
enrichment of Gene Ontology terms, which are arranged
hierarchically.
We have proposed weighted hypergeometric and chi-
squared methods to enrich gene sets. These methods can
produce more biologically relevant results for KEGG path-
way enrichment than the standard hypergeometric
approach, despite the fact that the problem of Type II
errors is inadequately addressed by correcting for multiple
comparisons. We also showed that our method tends to
produce more consistent results when using data from
similar experiments. Despite only showing the results of
KEGG pathway enrichment, these methods can also be
applied to the Gene Ontology classifications as well as any
other set of genes.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AS and RQ conceived of the methodology. RQ implemented the method,
and AS and RQ both contributed to the manuscript.
Declarations
The publication costs for this article were funded by the corresponding
author.
This article has been published as part of BMC Systems Biology Volume 7
Supplement 4, 2013: Selected articles from the IEEE International Conference
on Bioinformatics and Biomedicine 2012: Systems Biology. The full contents
of the supplement are available online at http://www.biomedcentral.com/
bmcsystbiol/supplements/7/S4.
Published: 23 October 2013
References
1. Ntzani EE, Ioannidis JPA: Predictive ability of DNA microarrays for cancer
outcomes and correlates: an empirical assessment. Lancet 2003,
362(9394):1439-1444.
2. van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M,
Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene
expression profiling predicts clinical outcome of breast cancer. Nature
2002, 415(6871):530-536.
3. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M,
McLaughlin ME, Kim JYH, Goumnerova LC, Black PM, Lau C, et al:
Prediction of central nervous system embryonal tumour outcome based
on gene expression. Nature 2002, 415(6870):436-442.
4. Simon R: Diagnostic and prognostic prediction using gene expression
profiles in high-dimensional microarray data. Br J Cancer 2003,
89(9):1599-1604.
5. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF,
Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, et al: NCBI GEO:
archive for functional genomics data sets–10 years on. Nucleic Acids
Research 2011, 39(suppl 1):D1005-D1010.
6. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene
expression and hybridization array data repository. Nucleic Acids Research
2002, 30(1):207-210.
7. Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R,
Farne A, Holloway E, Kolesnykov N, Lilja P, Lukk M, et al: ArrayExpress–a
public database of microarray experiments and gene expression profiles.
Nucleic Acids Research 2007, 35(suppl 1):D747-D750.
8. Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese JC,
Dwight SS, Kaloper M, Weng S, Jin H, Ball CA, et al: The Stanford
Microarray Database. Nucleic Acids Research 2001, 29(1):152-155.
9. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D,
Barrette T, Pandey A, Chinnaiyan AM: Large-scale meta-analysis of cancer
microarray data identifies common transcriptional profiles of neoplastic
transformation and progression. Proceedings of the National Academy of
Sciences of the United States of America 2004, 101(25):9309-9314.
10. Dawany N, Tozeren A: Asymmetric microarray data produces gene lists
highly predictive of research literature on multiple cancer types. BMC
Bioinformatics 2010, 11(1):483.
11. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K,
Lewis S, Marshall B, Mungall C, et al: The Gene Ontology (GO) database
and informatics resource. Nucleic Acids Research 2004, 32(Database):
D258-261.
12. Kanehisa M, Goto S: KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Research 2000, 28(1):27-30.
13. Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Research 2009, 37(1):1-13.
14. Khatri P, Sirota M, Butte AJ: Ten Years of Pathway Analysis: Current
Approaches and Outstanding Challenges. PLoS Comput Biol 2012, 8(2):
e1002375.
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment
analysis: A knowledge-based approach for interpreting genome-wide
expression profiles. Proceedings of the National Academy of Sciences of the
United States of America 2005, 102(43):15545-15550.
16. Kim S-Y, Volsky D: PAGE: Parametric Analysis of Gene Set Enrichment.
BMC Bioinformatics 2005, 6(1):144.
17. Rahnenfuhrer J, Domingues FS, Maydt J, Lengauer T: Calculating the
statistical significance of changes in pathway activity from gene
expression data. Stat Appl Genet Mol Biol 2004, 3:Article16.
18. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim J-s, Kim CJ,
Kusanovic JP, Romero R: A novel signaling pathway impact analysis.
Bioinformatics 2009, 25(1):75-82.
19. Qureshi R, Sacan A: A weighted hypergeometric statistic for the
enrichment of gene sets. Bioinformatics and Biomedicine (BIBM), 2012 IEEE
International Conference on: 4-7 Oct 2012 2012, 1-6.
20. Merskey H, Bogduk N: International Association for the Study of Pain.
Task Force on Taxonomy Classification of chronic pain : descriptions of chronic
pain syndromes and definitions of pain terms, 2nd edn Seattle: IASP Press;
1994.
21. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW: Symptoms and signs in
patients with suspected neuropathic pain. Pain 2004, 110(1-2):461-469.
22. Torrance N, Smith BH, Bennett MI, Lee AJ: The Epidemiology of Chronic
Pain of Predominantly Neuropathic Origin. Results From a General
Population Survey. The Journal of Pain 2006, 7(4):281-289.
23. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C: Prevalence of
chronic pain with neuropathic characteristics in the general population.
PAIN 2008, 136(3):380-387.
24. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of
neuropathic pain: an update and effect related to mechanism of drug
action. Pain 1999, 83(3):389-400.
25. Barclay J, Clark AK, Ganju P, Gentry C, Patel S, Wotherspoon G, Buxton F,
Song C, Ullah J, Winter J, et al: Role of the cysteine protease cathepsin S
in neuropathic hyperalgesia. PAIN 2007, 130(3):225-234.
26. Costigan M, Belfer I, Griffin RS, Dai F, Barrett LB, Coppola G, Wu T,
Kiselycznyk C, Poddar M, Lu Y, et al: Multiple chronic pain states are
associated with a common amino acid-changing allele in KCNS1. Brain
2010, 133(9):2519-2527.
27. Decosterd I, Woolf CJ: Spared nerve injury: an animal model of persistent
peripheral neuropathic pain. Pain 2000, 87(2):149-158.
28. Kim SH, Chung JM: An experimental model for peripheral neuropathy
produced by segmental spinal nerve ligation in the rat. Pain 1992,
50(3):355-363.
Qureshi and Sacan BMC Systems Biology 2013, 7(Suppl 4):S10
http://www.biomedcentral.com/1752-0509/7/S4/S10
Page 10 of 11
29. Drǎghici S, Khatri P, Martins RP, Ostermeier GC, Krawetz SA: Global
functional profiling of gene expression. Genomics 2003, 81(2):98-104.
30. Njau F, Geffers R, Thalmann J, Haller H, Wagner AD: Restriction of
Chlamydia pneumoniae replication in human dendritic cell by activation
of indoleamine 2,3-dioxygenase. Microbes and Infection 2009,
11(13):1002-1010.
31. Erbacher A, Gieseke F, Handgretinger R, Müller I: Dendritic cells: Functional
aspects of glycosylation and lectins. Human Immunology 2009,
70(5):308-312.
32. Ichikawa S, Hirabayashi Y: Glucosylceramide synthase and
glycosphingolipid synthesis. Trends in cell biology 1998, 8(5):198-202.
33. Uemura A, Watarai S, Iwasaki T, Kodama H: Induction of Immune
Responses against Glycosphingolipid Antigens: Comparison of Antibody
Responses in Mice Immunized with Antigen Associated with Liposomes
Prepared from Various Phospholipids. Journal of Veterinary Medical Science
2005, 67(12):1197-1201.
34. Levin ME, Jin JG, Ji R-R, Tong J, Pomonis JD, Lavery DJ, Miller SW,
Chiang LW: Complement activation in the peripheral nervous system
following the spinal nerve ligation model of neuropathic pain. PAIN
2008, 137(1):182-201.
35. von Schack D, Agostino MJ, Murray BS, Li Y, Reddy PS, Chen J, Choe SE,
Strassle BW, Li C, Bates B, et al: Dynamic Changes in the MicroRNA
Expression Profile Reveal Multiple Regulatory Mechanisms in the Spinal
Nerve Ligation Model of Neuropathic Pain. PLoS ONE 2011, 6(3):e17670.
36. Zhou Y, Zhou Z-S, Zhao Z-Q: Neomycin blocks capsaicin-evoked
responses in rat dorsal root ganglion neurons. Neuroscience Letters 2001,
315(1-2):98-102.
37. Van Den Wijngaard RM, Welting O, Bulmer DC, Wouters MM, Lee K, De
Jonge WJ, Boeckxstaens GE: Possible role for TRPV1 in neomycin-induced
inhibition of visceral hypersensitivity in rat. Neurogastroenterology &
Motility 2009, 21(8):863-e860.
38. Materazzi S, Nassini R, Andrè E, Campi B, Amadesi S, Trevisani M,
Bunnett NW, Patacchini R, Geppetti P: Cox-dependent fatty acid
metabolites cause pain through activation of the irritant receptor
TRPA1. Proceedings of the National Academy of Sciences 2008,
105(33):12045-12050.
39. Saxena V, Orgill D, Kohane I: Absolute enrichment: gene set enrichment
analysis for homeostatic systems. Nucleic Acids Research 2006, 34(22):e151.
40. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical
and Powerful Approach to Multiple Testing. Journal of the Royal Statistical
Society Series B (Methodological) 1995, 57(1):289-300.
41. Gold DL, Miecznikowski JC, Liu S: Error control variability in pathway-
based microarray analysis. Bioinformatics 2009, 25(17):2216-2221.
42. Bluthgen N, Brand K, Cajavec B, Swat M, Herzel H, Beule D: Biological
profiling of gene groups utilizing Gene Ontology. Genome informatics
International Conference on Genome Informatics 2005, 16(1):106-115.
doi:10.1186/1752-0509-7-S4-S10
Cite this article as: Qureshi and Sacan: Weighted set enrichment of gene
expression data. BMC Systems Biology 2013 7(Suppl 4):S10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Qureshi and Sacan BMC Systems Biology 2013, 7(Suppl 4):S10
http://www.biomedcentral.com/1752-0509/7/S4/S10
Page 11 of 11
